Building better measures for clinical trials with digital health technology

A major challenge for drug development is measuring improvement in a patient's condition with current assessment tools, such as a patient or clinician's report. In many cases these tools can be insensitive to change or unable to differentiate drug effects from placebo responses.

To address this challenge, companies across the pharmaceutical industry are now using digital health technology to objectively measure patient symptoms in clinical trials. Patients can complete daily tasks at home on a smartphone, or be recorded with wearables during their daily lives.

Early results indicate that these tools may help to address current measurement challenges. They have already contributed to internal company decision making for new drugs and in the future could be used to support regulatory approval of a drug or inform reimbursement decisions. In this seminar we will explore these measurement challenges, digital health technologies that are currently in use and the ways they are impacting drug development.

Wednesday, December 08, 2021
17:15 - 18:15
Online – Seminar
Host: Prof. D. Ricklin / Dr. L. Reutner
Molecular Pharmacy / Study Coordination